98%
921
2 minutes
20
Introduction: Left bundle branch area pacing (LBBAP) is typically performed using the lumenless (LLL) Medtronic SelectSecure Model 3830 pacing lead. Stylet-driven leads (SDL) for LBBAP were recently introduced.
Objective: To compare the Abbott Tendril STS 2088TC SDL and CPS Locator 3D delivery system to the Medtronic LLL and delivery system acutely and chronically.
Methods: Fifty consecutive patients who received SDL using the CPS Locator 3D delivery system for standard pacing indications were included in this study. A comparison was made with 229 LLL patients from a retrospective database, evaluating baseline characteristics, procedural outcomes, lead and system performance, and follow-up data.
Results: LBBAP was successful in 84% of SDL and 79% of LLL patients (p = 0.55), with no significant differences in procedural characteristics or complications. Minor pacing differences were noted. CPS Locator 3D performed similarly to C315His® delivery system with a trend for less lead placement attempts. Conduction system capture (CSC) pattern at implant did not differ between both groups. CSC maintenance was similar between SDL and LLL. However, follow-up QRS duration was significantly longer in SDL group (154 ms vs. 129 ms, p = 0.004), suggesting a possibility of CSC loss in some patients.
Conclusion: SDL is a viable alternative to LLL, demonstrating comparable acute and midterm pacing parameters. CPS Locator 3D delivery system showed comparable performance and an excellent safety profile. Acute CSC with SDL and LLL is similar, but its long-term maintenance will require further study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jce.70003 | DOI Listing |
Kidney360
September 2025
Department of Pediatrics, Division of Pediatric Nephrology, Baylor College of Medicine, Houston, TX, United States.
Background: Dialysis in neonates with ESKD is often associated with multiple comorbidities and the need for more intensified dialysis regimens. With recent advances in prenatal interventions and infant specific KRT, survival of neonates with ESKD has improved over the last decade. Little is known however about the impact on the health care system of improved survival in this population.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Department of Medicine, Institute for Transformative Molecular Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
The β-adrenergic receptor (βAR), a prototype G protein-coupled receptor, controls cardiopulmonary function underpinning O delivery. Abundance of the βAR is canonically regulated by G protein-coupled receptor kinases and β-arrestins, but neither controls constitutive receptor levels, which are dependent on ambient O. Basal βAR expression is instead regulated by the prolyl hydroxylase/pVHL-E3 ubiquitin ligase system, explaining O responsivity.
View Article and Find Full Text PDFMed Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDFCNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDF